Alzamend Neuro
ALZN · Nasdaq · United States
Share price · ALZN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALZN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026-9.0%
Nothing announced by ALZN that day or the session before.
- 3 Nov 2026+16.8%
Nothing announced by ALZN that day or the session before.
- 22 Oct 2026-10.4%
Nothing announced by ALZN that day or the session before.
- 1 Oct 2026-24.0%
Nothing announced by ALZN that day or the session before.
- 20 Aug 2026+7.2%
- 26 Jun 2026-7.0%
Nothing announced by ALZN that day or the session before.
- 20 May 2026+18.8%
Nothing announced by ALZN that day or the session before.
- 14 Apr 2026+15.7%
Nothing announced by ALZN that day or the session before.
- 27 Mar 2026-30.0%
- 26 Mar 2026-22.3%
Share of unusual movement by asset
For each asset, the share of ALZN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Lithium salicylate/L-proline (AL001)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 4% |
| Sessions with no dated event | — | 93% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | —Small molecule | Alzheimer's DiseaseBipolar Disorder |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
July 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $1.1M | $7.6M | $3.0M-$1.1M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $1.3M | $2.7M | $2.2M-$1.7M operating cash flow | report ↗ |
| 2025-Q4 | — | $0.2M | $4.5M | $1.0M-$1.2M operating cash flow | report ↗ |
| 2025-Q3 | — | $1.7M | $5.6M | $2.7M-$2.4M operating cash flow | report ↗ |
| 2025-Q1 | — | $0.5M | $3.4M | $1.0M-$1.4M operating cash flow | report ↗ |
| 2024-Q4 | — | $0.3M | $4.1M | $1.4M-$3.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $0.2M | $1.2M | $1.0M-$1.1M operating cash flow | report ↗ |
| 2024-Q1 | — | $1.9M | $0.3M | $2.7M-$2.0M operating cash flow | report ↗ |
| 2023-Q4 | — | $2.0M | $0.2M | $2.9M-$1.5M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.4M | $1.7M | $3.5M-$3.3M operating cash flow | report ↗ |
| 2023-Q1 | — | $2.9M | $7.4M | $5.4M-$1.8M operating cash flow | report ↗ |
| 2022-Q4 | — | $1.5M | $9.2M | $3.1M-$2.3M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.4M | $12M | $3.0M-$2.5M operating cash flow | report ↗ |
| 2022-Q1 | — | $0.9M | $12M | $2.6M-$1.8M operating cash flow | report ↗ |
| 2021-Q4 | — | $1.8M | — | $3.6M-$2.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $0.9M | — | $2.3M-$1.2M operating cash flow | report ↗ |
Annual history (6 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-FY | — | $3.6M | $0.7M | $2.2M-$8.1M operating cash flow | report ↗ |
Alzamend Neuro’s fiscal 2026 report (ended April 30, 2026) disclosed no revenue for the current or prior year. R&D spend was $3.63M, up 157.4% YoY, with cash and equivalents of $0.71M. The company reported a net loss of $8.77M and a quarterly net burn of $8.77M.
The clinical-stage biopharmaceutical company advanced its lead candidate AL001, reporting PK and PD topline data from the healthy-subject Lithium in Brain study and initiating a Phase II trial in bipolar disorder, with topline data expected in the fourth quarter of 2026. Full PK/PD results are expected in August 2026, MDD and PTSD trials are expected to commence in the fourth quarter of 2026, an Alzheimer’s trial is expected to begin in the first quarter of 2027, and the ALZN002 Phase I/IIA trial is expected to restart in the first quarter of 2027.
View 5 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $1.4M | $4.0M | $1.1M-$6.6M operating cash flow | report ↗ |
| 2024-FY | — | $6.5M | $0.4M | $2.5M-$8.3M operating cash flow | report ↗ |
| 2023-FY | — | $7.5M | $5.1M | $3.7M-$8.9M operating cash flow | report ↗ |
| 2022-FY | — | $5.2M | $14M | $3.1M-$6.6M operating cash flow | report ↗ |
| 2021-FY | — | $1.3M | $1.9M | $1.3M-$2.7M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 5 purchases ($331K), 3 sales ($14K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-26 | AULT MILTON C III · director | Open-market sale | 2,000 | $1.56 | $3K | Form 4 |
| 2026-07-31 | Hyperscale Data, Inc.; Ault Lending, LLC; Ault Capital Group, Inc. · director; director; director | Award / grant (derivative) | 7,500 | $1000.00 | $7.5M | Form 4 |
| 2026-07-31 | AULT MILTON C III · director | Award / grant (derivative) | 7,500 | $1000.00 | $7.5M | Form 4 |
| 2026-07-31 | Hyperscale Data, Inc. · director | Award / grant (derivative) | 7,500 | $1000.00 | $7.5M | Form 4 |
| 2026-04-14 | AULT MILTON C III · director | Open-market purchase | 108,388 | $1.00 | $109K | Form 4 |
| 2026-04-14 | AULT MILTON C III · director | Open-market purchase | 108,388 | $1.00 | $109K | Form 4 |
| 2026-04-14 | AULT MILTON C III · director | Open-market purchase | 2,000 | $1.03 | $2K | Form 4 |
| 2026-04-14 | AULT MILTON C III · director | Open-market purchase | 2,000 | $1.03 | $2K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.1M shares ($122K, 2.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 45,680 | $48K |
| 2 | VANGUARD FIDUCIARY TRUST CO | 21,020 | $22K |
| 3 | MORGAN STANLEY | 18,000 | $19K |
| 4 | Clearstead Advisors, LLC | 10,000 | $11K |
| 5 | Tower Research Capital LLC (TRC) | 6,184 | $7K |
| 6 | CITIGROUP INC | 5,231 | $6K |
| 7 | UBS Group AG | 4,504 | $5K |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 4,400 | $5K |
| 9 | BlackRock, Inc. | 437 | $463 |
| 10 | SBI Securities Co., Ltd. | 22 | $23 |
| 11 | Caitong International Asset Management Co., Ltd | 4 | $4 |
| 12 | HARBOR INVESTMENT ADVISORY, LLC | 1 | $1 |